Advocacy intelligence hub — real-time data for patient organizations
Nouscom SRL — PHASE1, PHASE2
National Cancer Institute (NCI) — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Omeprazole DR
AstraZeneca
Omeprazole
(OMEPRAZOLE)Orphan drugstandardPD-Rx Pharmaceuticals, Inc.
Proton Pump Inhibitor [EPC]
12.1 Mechanism of Action Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretio...
LONSURF
(trifluridine/tipiracil)Orphan drugstandardTaiho Oncology, Inc.
Nucleoside Analog Antiviral [EPC]
12.1 Mechanism of Action LONSURF consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil, ...
Keith T Flaherty
ECOG-ACRIN Cancer Research Group
📍 Birmingham, Alabama
Komal Jhaveri
ECOG-ACRIN Cancer Research Group
📍 NEW YORK, NY
Alisa M Goldstein, Ph.D.
National Cancer Institute (NCI)
📍 PITTSBURGH, PA
Shivaani Kummar, MD
NCI - Medical Oncology Branch
📍 PORTLAND, OR
Sven Gogov, MD
Nouscom SRL
Daniel Catenacci
University of Chicago Comprehensive Cancer Center
📍 CHICAGO, IL